🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 11 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 22/03/2011 | 45,23 | 46,26 | 44,95 | 46,16 | +1,92% | 2,90% | 2.011.400 |
| 21/03/2011 | 44,91 | 45,61 | 44,88 | 45,29 | +2,03% | 1,63% | 1.804.700 |
| 18/03/2011 | 44,68 | 44,90 | 44,15 | 44,39 | -0,36% | 1,68% | 2.680.000 |
| 17/03/2011 | 44,92 | 45,39 | 44,24 | 44,55 | +0,68% | 2,56% | 1.891.200 |
| 16/03/2011 | 45,48 | 45,48 | 44,01 | 44,25 | -3,19% | 3,23% | 2.603.700 |
| 15/03/2011 | 44,49 | 45,94 | 43,87 | 45,71 | +0,59% | 4,65% | 1.909.200 |
| 14/03/2011 | 46,01 | 46,40 | 45,35 | 45,44 | -2,17% | 2,28% | 1.425.300 |
| 11/03/2011 | 44,70 | 46,62 | 44,24 | 46,45 | +3,68% | 5,32% | 2.995.000 |
| 10/03/2011 | 46,72 | 46,80 | 44,63 | 44,80 | -5,55% | 4,64% | 3.091.700 |
| 09/03/2011 | 46,53 | 47,81 | 45,88 | 47,43 | +1,35% | 4,15% | 2.247.300 |
| 08/03/2011 | 48,89 | 48,99 | 46,60 | 46,80 | -5,68% | 4,89% | 5.682.200 |
| 07/03/2011 | 51,01 | 52,13 | 48,91 | 49,62 | -2,84% | 6,31% | 3.126.000 |
| 04/03/2011 | 49,86 | 51,10 | 49,07 | 51,07 | +2,24% | 4,07% | 3.641.300 |
| 03/03/2011 | 47,83 | 50,83 | 47,03 | 49,95 | +5,65% | 7,94% | 5.722.700 |
| 02/03/2011 | 46,07 | 47,82 | 46,01 | 47,28 | +2,69% | 3,93% | 2.873.200 |
| 01/03/2011 | 46,57 | 46,75 | 45,72 | 46,04 | -1,35% | 2,21% | 2.361.100 |
| 28/02/2011 | 44,92 | 46,75 | 44,34 | 46,67 | +4,08% | 5,37% | 3.279.700 |
| 25/02/2011 | 43,62 | 44,98 | 43,31 | 44,84 | +2,89% | 3,83% | 2.379.600 |
| 24/02/2011 | 43,70 | 43,97 | 43,24 | 43,58 | -0,89% | 1,67% | 3.029.900 |
| 23/02/2011 | 43,60 | 44,68 | 42,71 | 43,97 | +15,04% | 4,52% | 16.568.700 |
| 22/02/2011 | 38,74 | 39,15 | 38,00 | 38,22 | -2,40% | 2,97% | 1.776.300 |
| 18/02/2011 | 39,76 | 39,77 | 38,95 | 39,16 | -1,73% | 2,06% | 2.124.000 |
| 17/02/2011 | 39,50 | 39,99 | 39,40 | 39,85 | +0,50% | 1,49% | 945.700 |
| 16/02/2011 | 39,44 | 40,15 | 39,10 | 39,65 | +0,41% | 2,66% | 1.746.300 |
| 15/02/2011 | 38,77 | 39,51 | 38,76 | 39,49 | +1,33% | 1,93% | 1.350.500 |
| 14/02/2011 | 38,40 | 39,04 | 38,40 | 38,97 | +1,33% | 1,67% | 942.200 |
| 11/02/2011 | 38,13 | 38,52 | 37,77 | 38,46 | +0,79% | 1,97% | 1.670.900 |
| 10/02/2011 | 38,07 | 38,84 | 38,07 | 38,16 | +0,08% | 2,02% | 1.121.000 |
| 09/02/2011 | 38,40 | 38,59 | 38,07 | 38,13 | -0,91% | 1,35% | 849.700 |
| 08/02/2011 | 38,76 | 39,07 | 38,13 | 38,48 | +0,39% | 2,43% | 1.737.900 |